Sandbox Reserved 1791
From Proteopedia
(Difference between revisions)
Line 27: | Line 27: | ||
== Specific Residues and Interactions== | == Specific Residues and Interactions== | ||
[[Image:Salt bridge LYS.jpg|300 px|right|thumb|(Fig.2) Salt bridge interaction between LYS and Glu or Asp]] | [[Image:Salt bridge LYS.jpg|300 px|right|thumb|(Fig.2) Salt bridge interaction between LYS and Glu or Asp]] | ||
- | There are two <scene name='95/952719/Specific_residues/3'>lysine residues</scene> in the binding pocket of TSHR that are the main contributors to the binding of the antibodies. The concave structure of the binding pocket allows a <scene name='95/952719/Lock_and_key/5'>tight interaction</scene> with the antibodies. These antibodies make tight interactions with a lot of intermolecular forces at play. <scene name='95/952719/K---e_interaction/1'>LYS 58</scene> interacts with Glu 118 on the antibodies to make a [https://www.nature.com/articles/s41598-018-31935-z salt bridge interaction]. <scene name='95/952719/K---d_interaction/1'>LYS 209</scene> interacts with Asp 11 on the antibodies to make a salt bridge interaction. Specifically, the two residues make an ionic interaction. The interaction is not close enough to make a hydrogen bond. Instead, the interaction between the Lys residues with the Asp or Glu residues is a salt bridge interaction. This is the main bond that holds these two molecules together. When in the inactive form, LYS 209 does not interact with any residue but LYS 58 has interaction with Glu 118 and this interaction pulls the molecule into the bent position. The salt bridge interaction between Lys and Glu is very specific. Lys was mutated with Arg and was expected to make the same salt bride interaction with Glu, however it make a completely different interaction. This new interaction favors a gain of function towards [https://my.clevelandclinic.org/health/articles/22489-human-chorionic-gonadotropin hCG] <ref name=" | + | There are two <scene name='95/952719/Specific_residues/3'>lysine residues</scene> in the binding pocket of TSHR that are the main contributors to the binding of the antibodies. The concave structure of the binding pocket allows a <scene name='95/952719/Lock_and_key/5'>tight interaction</scene> with the antibodies. These antibodies make tight interactions with a lot of intermolecular forces at play. <scene name='95/952719/K---e_interaction/1'>LYS 58</scene> interacts with Glu 118 on the antibodies to make a [https://www.nature.com/articles/s41598-018-31935-z salt bridge interaction]. <scene name='95/952719/K---d_interaction/1'>LYS 209</scene> interacts with Asp 11 on the antibodies to make a salt bridge interaction. Specifically, the two residues make an ionic interaction. The interaction is not close enough to make a hydrogen bond. Instead, the interaction between the Lys residues with the Asp or Glu residues is a salt bridge interaction. This is the main bond that holds these two molecules together. When in the inactive form, LYS 209 does not interact with any residue but LYS 58 has interaction with Glu 118 and this interaction pulls the molecule into the bent position. The salt bridge interaction between Lys and Glu is very specific. Lys was mutated with Arg and was expected to make the same salt bride interaction with Glu, however it make a completely different interaction. This new interaction favors a gain of function towards [https://my.clevelandclinic.org/health/articles/22489-human-chorionic-gonadotropin hCG] <ref name="Guillaume"> DOI:10.1210/mend.16.4.0815</ref> |
== Biological Relevance == | == Biological Relevance == |
Revision as of 04:18, 7 April 2023
This Sandbox is Reserved from February 27 through August 31, 2023 for use in the course CH462 Biochemistry II taught by R. Jeremy Johnson at the Butler University, Indianapolis, USA. This reservation includes Sandbox Reserved 1765 through Sandbox Reserved 1795. |
To get started:
More help: Help:Editing |
Thyroid Stimulating Hormone Receptor (TSHR)
|
References
- ↑ 1.0 1.1 1.2 Faust B, Billesbolle CB, Suomivuori CM, Singh I, Zhang K, Hoppe N, Pinto AFM, Diedrich JK, Muftuoglu Y, Szkudlinski MW, Saghatelian A, Dror RO, Cheng Y, Manglik A. Autoantibody mimicry of hormone action at the thyrotropin receptor. Nature. 2022 Aug 8. pii: 10.1038/s41586-022-05159-1. doi:, 10.1038/s41586-022-05159-1. PMID:35940205 doi:http://dx.doi.org/10.1038/s41586-022-05159-1
- ↑ Duan J, Xu P, Luan X, Ji Y, He X, Song N, Yuan Q, Jin Y, Cheng X, Jiang H, Zheng J, Zhang S, Jiang Y, Xu HE. Hormone- and antibody-mediated activation of the thyrotropin receptor. Nature. 2022 Aug 8. pii: 10.1038/s41586-022-05173-3. doi:, 10.1038/s41586-022-05173-3. PMID:35940204 doi:http://dx.doi.org/10.1038/s41586-022-05173-3
- ↑ doi: https://dx.doi.org/10.1134/S0022093022050143
- ↑ Smits G, Govaerts C, Nubourgh I, Pardo L, Vassart G, Costagliola S. Lysine 183 and glutamic acid 157 of the TSH receptor: two interacting residues with a key role in determining specificity toward TSH and human CG. Mol Endocrinol. 2002 Apr;16(4):722-35. PMID:11923469 doi:10.1210/mend.16.4.0815
- ↑ 5.0 5.1 Chiovato L, Magri F, Carlé A. Hypothyroidism in Context: Where We've Been and Where We're Going. Adv Ther. 2019 Sep;36(Suppl 2):47-58. PMID:31485975 doi:10.1007/s12325-019-01080-8